http://venturebeat.disqus.com/News about Tech, Business and InnovationenWed, 22 Aug 2007 17:23:06 -0000http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/#comment-14677851<p>That's certainly plausible, but I tend to think they're actually headed in the other direction. This is from the summary section of BioForm's S-1:<br></p><blockquote>Our strategy is to become a worldwide leader in medical aesthetics by building on our success with Radiesse, gaining a market leading position in dermal fillers, enhancing the strength of our sales and marketing organizations in the United States and Europe and commercializing new products beyond dermal fillers that enhance the practice of medical aesthetics.</blockquote>David HamiltonWed, 22 Aug 2007 17:23:06 -0000http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/#comment-14677850<p>Actually, you could interpret bioform's filing the other way around. That is, they'd like to be more "medical" and might be making efforts in that way (haven't read the S-1). But if the reality is that all their revenue is esthetic, they pretty much have to describe themselves that way for the SEC's benefit.</p>DV Henkel-WallaceWed, 22 Aug 2007 14:58:50 -0000